Brief: Diamedica Therapeutics Announces Enrollment Of 200Th Patient In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial
22/10/2026 14:28
BRIEF-Diamedica Therapeutics Announces Enrollment Of 200Th Patient In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial Oct 22 (Reuters) - DiaMedica Therapeutics Inc DMAC.O:
DIAMEDICA THERAPEUTICS ANNOUNCES ENROLLMENT OF 200TH PATIENT IN REMEDY2 PHASE 2/3 ACUTE ISCHEMIC STROKE TRIAL
DIAMEDICA THERAPEUTICS - INTERIM ANALYSIS RESULTS EXPECTED IN Q1 2027
Source text: ID:nBw39kzTa
Further company coverage: DMAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DiaMedica Therapeutics
See all newsBrief: Diamedica Therapeutics Announces Enrollment Of 200Th Patient In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Q2 net loss widen less than expected
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood
Brief: Diamedica Receives FDA Feedback On Dm199 Preeclampsia Nonclinical Program